MHRA Drug Safety Update March 2020

MHRA Drug Safety Update March 2020

March 18, 2020

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 13 Issue 3 October 2019) has been published and includes articles on:

  • Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury
  • Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections
  • Baricitinib (Olumiant▼): risk of venous thromboembolism
  • SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
  • Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
  • Letters and drug alerts sent to healthcare professionals in February 2020 
  • Medical Device Alerts issued in February 2020

To see the latest MHRA Drug Safety Update in full, visit the website.

Posted in: ,

More Latest News >

Funding for Easter opening hours

Further to NHS England and NHS Improvement’s (NHSE&I) decision that community pharmacies in England must open between 2pm and 5pm...